RBC Capital says that the near-term outlook for Regneron's (REGN) Praluent for LDL-C lowering is unchanged after Amgen (AMGN) was granted approval of a competing drug and The Medicines Co (MDCO) and Alnylam (ALNY) reported favorable Phase I data for their competing drug candidate. The firm says that Amgen's drug has many similarities to Praluent, while the outlook for the other treatment is still uncertain. Moreover, RBC says that Regeneron has at least seven other treatments with much greater potential than Praluent. RBC keeps a $665 price target and Outperform rating on Regeneron.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).